Parameter | Number | Percentage |
---|---|---|
Ages | 20–64 | 40.4 ± 11.1 |
 Pre-menopause | 77 | 90.60% |
 Post-menopause | 8 | 9.40% |
HR-HPV positive genotype | 72 | 84.70% |
 HPV16 | 9 | 10.60% |
 HPV18 | 8 | 9.40% |
 aOther 12 HR-HPV types | 45 | 52.90% |
 HPV16 + 18 | 2 | 2.40% |
 HPV16 + Other 12 types | 6 | 7.10% |
 HPV16 + 18 + Other 12 types | 2 | 2.40% |
HR-HPV negative genotype | 13 | 15.30% |
P16 | ||
 Positive | 48 | 56.50% |
 Negative | 37 | 43.50% |
Ki67 | ||
 High expression | 45 | 52.90% |
 Low expression | 40 | 47.10% |
CIN | ||
 CIN1 | 29 | 34.10% |
 CIN2 | 31 | 36.50% |
 CIN3 | 25 | 29.40% |
Grouping | ||
 Control | 49 | 57.60% |
 Test | 36 | 42.40% |